Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser eye treatment may impact corneal cells, new study warns

NCT ID NCT07157553

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether argon laser treatment for advanced diabetic eye disease (proliferative diabetic retinopathy) changes the number of cells in the cornea. Researchers will measure corneal cell density before and after laser treatment in 45 patients. The goal is to see if the laser causes any harm to the cornea, which is important for keeping vision clear.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
argon laser panretinal photocoagulation
What this could lead to
If it works, this could help doctors understand if laser treatment for diabetic eye disease harms the cornea, leading to safer procedures.
What could go wrong
This is a small, early observational study with only 45 people. It measures a cell count, not vision outcomes, so the real-world impact is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of 45 newly diagnosed patients of any age or sex with proliferative diabetic retinopathy who require panretinal photocoagulation. The inclusion criteria cover patients irrespective of age or sex who are newly diagnosed with proliferative diabetic retinopathy and are indicated for argon laser panretinal photocoagulation. Exclusion criteria include any history of corneal disease, previous intraocular surgeries, glaucoma, or intraocular inflammation to reduce confounding factors affecting corneal endothelial measurements. This helps to ensure that changes detected in corneal endothelial cell density and morphology are primarily attributable to the laser intervention rather than underlying ocular comorbidities

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients from either sex with any age newly diagnosed PDR requring PRP . Exclusion Criteria: * history of corneal disease * previous intraocular surgery * glaucoma or intraocuar inflamation .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Panretinal photocoagulation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

proliferative diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Panretinal photocoagulation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.